Cambridge Cognition - Director/PDMR Share Purchases

Cambridge Cognition Holdings

23/09/2026 17:10

		
		
		
		
		
	
	
RNS Number : 0498W
  
Cambridge Cognition Holdings PLC
  
23 September 2026
  
 

		

			

				23 September 2026
			
			

				 
			
			

				Cambridge Cognition Holdings plc
			
			

				("Cambridge Cognition", the "Company" or the "Group")
			
			

				 
			
			

				Director/PDMR Share Purchases
			
			

				 
			
			

				Cambridge Cognition Holdings plc (AIM: COG), the neuroscience technology company, was informed on 18 September 2026 that, on the same day, Nick Rodgers, Non-Executive Chair of the Company, purchased 19,000 ordinary shares of 0.01 pence each ("Ordinary Shares") in the Company at a price of 27.4 pence per share.
			
			

				 
			
			

				Following this transaction, Nick Rodgers holds an interest in 98,892 Ordinary Shares, representing approximately 0.18% of the Company's issued share capital.
			
			

				 
			
			

				Further information on the purchases is contained in the disclosure tables below.
			
			

				 
			
			

				NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:
			
			

				 
			
			

				

					

						

							1
						
					
					

						

							Details of the person discharging managerial responsibilities / person closely associated
						
					
				
				

					

						

							a)
						
					
					

						

							Name
						
					
					

						

							Nick Rodgers
						
					
				
				

					

						

							2
						
					
					

						

							Reason for the notification
						
					
				
				

					

						

							a)
						
					
					

						

							Position/status
						
					
					

						

							Non-Executive Director
						
					
				
				

					

						

							b)
						
						

							 
						
					
					

						

							Initial notification /Amendment
						
					
					

						

							Initial notification
						
					
				
				

					

						

							3
						
						

							 
						
					
					

						

							Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
						
					
				
				

					

						

							a)
						
					
					

						

							Name
						
					
					

						

							Cambridge Cognition Holdings plc
						
					
				
				

					

						

							b)
						
					
					

						

							LEI
						
					
					

						

							213800SZKDIN122EPA96
						
					
				
				

					

						

							4
						
						

							 
						
					
					

						

							Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
						
					
				
				

					

						

							a)
						
						

							 
						
					
					

						

							Description of the financial instrument, type of instrument
						
						

							Identification code
						
					
					

						

							Ordinary shares of 0.01p each
						
						

							 
						
						

							 
						
						

							GB00B8DV9647
						
					
				
				

					

						

							b)
						
					
					

						

							Nature of the transaction
						
					
					

						

							Purchase of Shares
						
					
				
				

					

						

							c)
						
					
					

						

							Price(s) and volume(s)
						
					
					

						

							

								

									

										  Price(s)
									
								
								

									

										Volume(s)
									
								
							
							

								

									

										27.4 pence
									
								
								

									

										19,000
									
								
							
						
						

							 
						
					
				
				

					

						

							d)
						
					
					

						

							Aggregated information
						
						

							- Aggregated volume
						
						

							- Price
						
					
					

						

							N/A
						
						

							 
						
						

							 
						
					
				
				

					

						

							e)
						
					
					

						

							Date of the transaction
						
					
					

						

							18 September 2026
						
					
				
				

					

						

							f)
						
					
					

						

							Place of the transaction
						
					
					

						

							London Stock Exchange
						
						

							 
						
					
				
			
			

				 
			
			

				ENQUIRIES
			
			

				

					

						

							 
						
						

							Cambridge Cognition Holdings plc 
						
						

							Rob Baker, Chief Executive Officer
						
						

							Ronald Openshaw, Chief Financial Officer
						
						

							 
						
					
					

						

							 
						
						

							Tel: 01223 810700 
						
						

							press@camcog.com 
						
					
				
				

					

						

							Cavendish Capital Markets Limited (NOMAD and Joint Broker) 
						
						

							Geoff Nash / Elysia Bough / Joe Smith
						
						

							Harriet Ward
						
						

							Nigel Birks
						
					
					

						

							Tel: 020 7220 0500 
						
						

							Corporate Finance
						
						

							Corporate Broking
						
						

							LS Specialist Sales
						
					
				
				

					

						

							 
						
						

							Singer Capital Markets Limited (Joint Broker) 
						
						

							Amber Higgs / Paul Richards / Daniel Ingram
						
					
					

						

							 
						
						

							Tel: 020 7496 3000
						
						

							 
						
					
				
			
			

				 
			
			

				 
			
			

				NOTES TO EDITORS
			
			

				 
			
			

				ABOUT CAMBRIDGE COGNITION 
			
			

				Cambridge Cognition is a neuroscience technology company whose digital cognitive assessments support scientific discovery, accelerate drug development and improve patient care.  
			
			

				 
			
			

				The Company has developed a suite of touchscreen and voice-based cognitive assessments delivered under the CANTAB and Winterlight brands.  These assessments are designed to: 
			
			

				 
			
			

				

					require minimal specialist administration 
				
				

					deliver objective results in real time or shortly after completion 
				
				

					reduce administrator bias 
				
				

					support longitudinal monitoring of cognitive function 
				
			
			

				 
			
			

				Assessment results can be presented in formats appropriate for both consumers in home-use settings and healthcare professionals in clinical or research environments.  
			
			

				 
			
			

				CANTAB Pathway™ is Cambridge Cognition’s latest scalable cognitive assessment solution, structured as an escalating series of tasks for use in consumer and healthcare settings: 
			
			

				 
			
			

				

					CANTAB One – a brief assessment of overall cognitive function 
				
				

					CANTAB Insight™ – a three-task battery providing deeper insight across five cognitive sub-domains 
				
				

					CANTAB Plus – specialist disease-specific modules for use by appropriately qualified healthcare professionals, covering eight indications including Parkinson’s disease, ADHD, multiple sclerosis, Huntington’s disease, schizophrenia, depression, and Alzheimer’s disease and related dementias 
				
			
			

				 
			
			

				For further information, visit: www.cambridgecognition.com  
			
			

				 
			
			

				 
			
		
	
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHPPUBUBUPQGQW